STOCKS | U.K. Approves Enhertu for NHS Use as Drug Deal Costs Draw Audit Calls

The U.K. National Institute for Health and Care Excellence has approved Enhertu for use in England's National Health Service, with about 1,000 women with advanced breast cancer expected to benefit each year. According to Sina Finance, the decision has drawn criticism over the cost of the U.K.-U.S. drug agreement, and lawmakers are calling for an investigation by the National Audit Office.